Infralimbic Estradiol Enhances Neuronal Excitability and Facilitates Extinction of Cocaine Seeking in Female Rats via a BDNF/TrkB Mechanism

Hanna Yousuf 1, Chad W. Smies 1, Madalyn Hafenbreidel 1, Jennifer J. Tuscher 1, Ashley M. Fortress 1, Karyn M. Frick 1 and Devin Mueller 1,2*

1Department of Psychology, University of Wisconsin–Milwaukee, Milwaukee, WI, United States, 2Department of Biological Sciences, Kent State University, Kent, OH, United States

OPEN ACCESS

Women are more susceptible to developing cocaine dependence than men, but paradoxically, are more responsive to treatment. The potent estrogen, 17β-estradiol (E2), mediates these effects by augmenting cocaine seeking but also promoting extinction of cocaine seeking through E2’s memory-enhancing functions. Although we have previously shown that E2 facilitates extinction, the neuroanatomical locus of action and underlying mechanisms are unknown. Here we demonstrate that E2 infused directly into the infralimbic-medial prefrontal cortex (IL-mPFC), a region critical for extinction consolidation, enhances extinction of cocaine seeking in ovariectomized (OVX) female rats. Using patch-clamp electrophysiology, we show that E2 may facilitate extinction by potentiating intrinsic excitability of IL-mPFC neurons. Because the mnemonic effects of E2 are known to be regulated by brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related kinase B (TrkB), we examined whether BDNF/TrkB signaling was necessary for E2-induced enhancement of excitability and extinction. We found that E2-mediated increases in excitability of IL-mPFC neurons were abolished by Trk receptor blockade. Moreover, blockade of TrkB signaling impaired E2-facilitated extinction of cocaine seeking in OVX female rats. Thus, E2 enhances IL-mPFC neuronal excitability in a TrkB-dependent manner to support extinction of cocaine seeking. Our findings suggest that pharmacological enhancement of E2 or BDNF/TrkB signaling during extinction-based therapies would improve therapeutic outcome in cocaine-addicted women.

Keywords: cocaine abuse, conditioned place preference (CPP), estrogens, brain-derived neurotrophic factor, electrophysiology, intrinsic excitability, extinction learning, medial prefrontal cortex (mPFC)
INTRODUCTION

Susceptibility to developing cocaine abuse disorders is higher in females than in males, an effect mediated by the actions of estrogens (McCance-Katz et al., 1999; Elman et al., 2001; Lynch et al., 2002; O’Brien and Anthony, 2005; Lejuez et al., 2007; Becker and Hu, 2008; Evans and Foltin, 2010). Previous work has shown that the potent form of estrogen, 17β-estradiol (E$_2$), promotes formation and expression of drug-related memories in females (Lynch et al., 2001; Larson et al., 2007; Evans and Foltin, 2010; Bobzean et al., 2014; Segarra et al., 2014; Doncheck et al., 2018) and enhances learning and memory across multiple behavioral paradigms (Daniel, 2006; Frick, 2012, 2015). Paradoxically, the mnemonic effects of E$_2$ facilitate extinction of cocaine seeking in female rats and lack of E$_2$ in ovariectomized (OVX) female rats results in extinction failure leading to perseverative cocaine seeking across more than 40 days (Twining et al., 2013). Systemic administration of E$_2$, however, rescues extinction learning in these rats (Twining et al., 2013). Extinction memories to suppress fear- and drug-associated behaviors are consolidated in the infralimbic-medial prefrontal cortex (IL-mPFC; Quirk et al., 2000; Peters et al., 2008; Quirk and Mueller, 2008; Torregrossa and Taylor, 2013), but the effects of E$_2$ in this region on neuronal function and extinction learning are unknown. Previous work has demonstrated that E$_2$ alters dorsal hippocampus (DH) function, enhancing neuronal excitability during the proestrus (high E$_2$) phase relative to the metestrus (low E$_2$) phase of the rat estrous cycle (Scharfman et al., 2003). Whether E$_2$ acts within IL-mPFC to promote extinction learning and alter IL-mPFC neuronal excitability remains to be determined.

E$_2$ may promote learning-related plasticity and intrinsic excitability by targeting neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tropomyosin-related kinase B (TrkB; Singh et al., 1995; Aguirre and Baudry, 2009; Hill, 2012; Wu et al., 2013; Fortress et al., 2014; McCarthy et al., 2018; Lu et al., 2019). For example, a single subcutaneous injection or direct infusions of E$_2$ into the hippocampus increase BDNF protein levels in this region (Gibbs, 1999; Fortress et al., 2014). Furthermore, bath-application of a Trk receptor antagonist, K-252a, to hippocampal slices attenuates neuronal excitability during the proestrus (high E$_2$) phase of the rat estrous cycle (Scharfman et al., 2003), suggesting that E$_2$ may enhance neuronal excitability via a BDNF/Trk-dependent mechanism. Whether the interaction between E$_2$ and BDNF/Trk signaling is necessary for IL-mPFC neuronal excitability and whether this interaction supports extinction learning remains unknown.

Using a cocaine conditioned place preference (CPP) paradigm, we determined if infusions of E$_2$ in IL-mPFC would facilitate extinction of cocaine seeking in OVX female rats. To assess the physiological effects of E$_2$, we used patch-clamp electrophysiology to investigate if bath-application of E$_2$ would enhance intrinsic excitability of IL-mPFC neurons and whether E$_2$-mediated excitability could be prevented in the presence of Trk receptor antagonists. Additionally, we tested whether E$_2$-BDNF interactions were necessary for extinction of a cocaine CPP in OVX female rats. Our results reveal that E$_2$ enhances excitability in IL-mPFC neurons via BDNF/Trk signaling to promote extinction of a cocaine CPP.

MATERIALS AND METHODS

Subjects and Surgery

Female Long-Evans rats weighing between 275 and 300 g were individually housed in clear plastic cages. Rats were maintained on a 14-h light/10-h dark cycle and had unlimited access to water and standard laboratory chow (Teklad, Harlan Laboratories). Rats were weighed and handled daily for approximately 3 days prior to surgery and before the start of experiments. All experimental protocols were approved by the Institutional Animal Care and Use Committee at the University of Wisconsin-Milwaukee in accordance with National Institute of Health guidelines.

Surgeries were performed as previously described (Frick et al., 2004; Otis et al., 2013; Twining et al., 2013). Rats were anesthetized with a mixture of ketamine/xylazine (90/10.5 mg/kg, i.p.) and underwent bilateral OVX using a dorsal approach (Frick et al., 2004). A single, horizontal incision was made along the spine and the ovary was isolated. The tip of the uterus was clamped and ligated and the ovary was removed with a scalpel. The remaining tissue was returned to the abdomen. The same procedure was repeated on the other ovary, and the incision was closed with sterile sutures and wound clips. For infusion experiments, rats were implanted with a double-barrel guide cannula aimed bilaterally at IL-mPFC (anteriorposterior, +2.8; mediolateral ±0.6, and dorsoventral, −4.4 mm relative to bregma). Following surgeries, rats were given an antibiotic (penicillin G procaine, 75,000 units in 0.25 mL) and an analgesic (carprofen, 5.0 mg in 0.1 mL) subcutaneously and then allowed to recover for approximately 10 days before behavioral testing.

Drugs

Cocaine HCl (National Institute on Drug Abuse) was dissolved in sterile 0.9% saline at a concentration of 10 mg/mL, and administered systemically at a dose of 10 mg/kg, i.p. To ensure that E$_2$ levels did not build over time from repeated infusions, a water-soluble form of E$_2$ dissolved in 2-hydroxypropyl-β-cyclodextrin (HBC) that is metabolized within 24 h was used (Pitha and Pitha, 1985). HBC vehicle and HBC-encapsulated E$_2$ were dissolved in sterile 0.9% saline (0.2 mg/mL) and injected i.p. at a dose of 0.2 mg/kg (Gresack and Frick, 2006) or directly infused into IL-mPFC at 5 µg/0.5 µl/side (Fernandez et al., 2008). ANA-12 (selective TrkB receptor antagonist) was dissolved in 1% DMSO in physiological saline (Zhang et al., 2015) and administered i.p. at 0.5 mg/kg (Cazorla et al., 2011). For electrophysiological recordings, 25 nM β-estradiol (not HBC encapsulated) was dissolved in 100% DMSO and diluted with artificial cerebral spinal fluid (aCSF) to a final DMSO concentration of 0.0001%. K-252a (Trk receptor antagonist) was dissolved in 100% DMSO and bath-applied at 100 nM and
diluted with aCSF to a final concentration of 0.001% DMSO (Montalbano et al., 2013).

**Patch-Clamp Electrophysiology**

Female rats aged 3 months were OVXed and allowed to recover for 7 days. Rats received systemic injections of E$_2$ or HBC vehicle for 3 days before being euthanized for patch-clamp recordings. They were anesthetized with isoflurane, and their brains were rapidly removed and transferred to ice-cold, oxygenated (95%/O$_2$/5% CO$_2$) aCSF containing the following composition (in mM): 124 NaCl, 2.8 KCl, 1.25 NaH$_2$PO$_4$, 2 MgSO$_4$, 2 CaCl$_2$, 26 NaHCO$_3$, and 20 dextrose. Coronal slices were cut 400 µM in ice-cold aCSF using a vibrating blade microtome (Leica VT1200). Slices recovered in warm aCSF (32–35°C) for 30 min followed by incubation in room-temperature aCSF for the remainder of the experiment. Slices were transferred to a submersion chamber, mounted, and perfused with aCSF (~2 ml/min; room temperature). Pyramidal neurons with visible apical dendrites in layer 5 of the IL-mPFC were visualized with differential interference contrast using a 60× water-immersion lens on an upright Eclipse FN1 microscope (Nikon Instruments). Whole-cell patch recordings of IL-mPFC pyramidal neurons were obtained using fire polished borosilicate glass pipettes (3–8 MΩ), filled with internal solution containing the following (in mM): 110 K-gluconate, 20 KCl, 10 HEPES, 2 MgCl$_2$, 2 ATP, 0.3 GTP, 10 phosphocreatine; 0.2% biocytin, pH 7.3, and 290 mOsm. Intrinsic excitability was obtained with current clamp using a MultiClamp 700B (Molecular Devices) patch-clamp amplifier connected to a Digidata 1440A digitizer (Molecular Devices). The liquid-liquid junction potential (measured as 13 mV) was compensated for all recordings. All electrophysiological data were analyzed using Clampfit (Molecular Devices).

After 10 min of stable recordings, layer 5 IL-mPFC neurons were polarized to approximately −60 mV to control for variance in resting membrane potential. A series of 1 s current steps were applied (~40 to 500 pA; 10 pA steps) and the number of evoked action potentials (APs) was recorded to measure basic membrane properties (Table 1). To measure input resistance, current pulses were injected and the resulting voltage deflections were measured to create a V-I plot. Furthermore, rheobase was measured, which is the minimum amount of current required to elicit a single AP. Rheobase was analyzed in a subset of layer 5 pyramidal neurons by applying 1 s current steps with 10 pA increments until a single AP was elicited. Intrinsic excitability was measured by applying a 2 s depolarizing step every 7.5 s and evoked APs were recorded. The level of depolarizing step was adjusted to rheobase and remained constant throughout the experiment (Otis et al., 2013). To measure effects of E$_2$ on intrinsic excitability, 25 nM of E$_2$ was bath-applied and baseline current steps were applied every 5 min for approximately 30 min. To ensure that excitability was enhanced by E$_2$ and not by the current pulses on its own, the same protocols were repeated for the same amount of time in slices that remained in aCSF and did not receive any E$_2$ treatment. To measure the effects of K-252a on E$_2$-induced excitability, slices were bathed with aCSF to a final concentration of 0.001% DMSO (Montalbano et al., 2013).

| Group          | Time  | $V_{rest}$ (mV) | $R_i$ (MΩ) | $V_{Th}$ (mV) | $R_{h}$ (MΩ) | $A_H$ (mV) | $mA_H$ (ms) | $fA_H$ (ms) | $sA_H$ (ms) |
|---------------|-------|----------------|------------|---------------|--------------|------------|-------------|-------------|-------------|
| Pre E$_2$     |       |               |            |               |              |            |             |             |             |
| Post E$_2$    |       |               |            |               |              |            |             |             |             |
| Pre E$_2$ + K252a |     |               |            |               |              |            |             |             |             |
| Post E$_2$ + K252a |   |               |            |               |              |            |             |             |             |

**Table 1** | Effects of E$_2$ on intrinsic excitability of infralimbic-medial prefrontal cortex (IL-mPFC) pyramidal neurons.

$^a$ $p < 0.001$.
in 100 nM K-252a (Montalbano et al., 2013) for approximately 20 min before bath-application of E₂. Following recording, brain slices were fixed in phosphate-buffered formalin overnight.

To confirm that patch-clamp recordings were from layer 5 IL-mPFC neurons, biocytin-filled pyramidal neurons were washed in 0.1 M phosphate-buffered saline (PBS), followed by 1% NaBH₄ in PBS and 10% normal goat serum. The slices were incubated overnight with 3% NGS, 0.2% Triton-X, and PBS. After 24 h, slices were washed in PBS and incubated for 2 h with a green fluorescent antibody (streptavidin, 1:250). Slices were washed with PBS before being mounted with antifade mounting medium and coverslipped and were visualized using 20× magnification with green fluorescent light, to locate neurons and verify that they were pyramidal.

Electrophysiological data were analyzed using Clampfit (Molecular Devices). Basic neuron properties were examined: input resistance, resting membrane potential, AP half-width, AP amplitude, and AP threshold (Table 1). To analyze slow afterhyperpolarization (sAHP), voltage was recorded 1 s following current offset, which was then subtracted from baseline voltage before current injection (Kaczorowski et al., 2012). To analyze medium AHP (mAHP), voltage was recorded 150 ms following current offset, which was then subtracted from baseline voltage before current injection (Song et al., 2015). Fast AHP (fAHP) was measured as the antipeak amplitude relative to AP threshold (Song and Moyer, 2017), which was then subtracted from baseline. Basic measures of intrinsic excitability were analyzed using independent samples t-test before and immediately following drug application. To analyze number of APs, the average number of spikes was plotted against time. Repeated-measures ANOVA was used to compare excitability across time and between groups.

**Conditioned Place Preference**

Testing and conditioning were conducted in a 3-chamber apparatus in which two larger conditioning chambers (33 × 23 × 29 cm) were separated by a smaller chamber (15 × 18 × 29 cm). The larger conditioning chambers had wire mesh flooring with white walls, whereas the other had gold-grated flooring with a black wall. The center chamber had aluminum sheeting as flooring. All floors were raised 4 cm, with removable trays placed beneath. Removable partitions were used to isolate the rats within specific chambers during conditioning. During baseline and CPP trials, the doors were removed to allow free access to the entire apparatus. Each of the larger chambers contained two infrared photobeams separated by 8 cm. If the beam furthest from the door was broken, then the rat was considered to be in the larger chamber. If only the beam closest to the center chamber was broken, then the rat was considered to be in the center chamber. During all phases of the experiments, the room was kept in semi-darkness.

A pre-test determined baseline preferences by placing the rats into the center chamber with free access to the entire apparatus for 15 min and recording time in each chamber. Rats spent an equal amount of time in the larger conditioning chambers, but less time in the center chamber. ANOVA revealed an effect of chamber for all rats during baseline test ($F_{(2,204)} = 98.73$, $p < 0.001$), and post hoc analyses confirmed that less time was spent in the center chamber than either of the conditioning chambers ($p < 0.001$). Therefore, an unbiased procedure was used, in which rats were randomly assigned to receive cocaine in one of the two larger chambers, independent of baseline preference scores. After a pre-test, rats were conditioned to associate one chamber, but not another, with cocaine in a counterbalanced fashion over 8 days. Systemic cocaine injections were given immediately before placing the rats in their chambers for 20 min conditioning sessions. Following conditioning, rats went through extinction training in which they were placed into the center chamber and allowed free access to the entire apparatus for 15 min.

All rats received daily 0.2 mg/kg, i.p. (Gresack and Frick, 2006) injections of E₂ throughout the conditioning phase. Rats received E₂ treatment 1 h before eight conditioning trials. Conditioning trials consisted of four pairings with cocaine and four pairings with saline. Following conditioning, rats remained in their homecages for 2 days. To test whether infusions of E₂ in IL-mPFC facilitated extinction, HBC vehicle and HBC-encapsulated E₂ (0.5 µg/0.5 µl/side; Fernandez et al., 2008) were directly infused in IL-mPFC 5 min prior to each extinction trial. We examined whether inactivation of TrkB receptors impairs extinction by systemically administering the selective TrkB receptor antagonist, ANA-12. One hour prior to each extinction trial (15 min), rats received either systemic injections of 0.2 mg/kg, i.p. E₂ (Gresack and Frick, 2006) and 0.5 mg/kg, i.p. ANA-12 (Cazorla et al., 2011; Zhang et al., 2015) or E₂ and vehicle. ANA-12 was systemically administered 1 h prior to a CPP trial because active concentrations have been detected as early as 30 min and up to 6 h after systemic injections (Cazorla et al., 2011).

After behavioral testing, rats were euthanized with an overdose of ketamine and perfused with 0.9% saline followed by 10% phosphate-buffered formalin. Brains were removed and placed in 30% sucrose/formalin solution. Following brain submersion, 40 µM thick coronal sections were sliced using a microtome from brain regions in which cannula were implanted. Sections were then mounted and stained with cresyl violet. Injector tip locations were confirmed using a rat brain atlas (Paxinos and Watson, 2007).

Drug-seeking behavior was analyzed using a three-way ANOVA to compare time within each chamber across trials and between groups (Twining et al., 2013; Otis et al., 2014). When appropriate main interaction effects were detected, Fisher’s LSD post hoc tests were used to make pairwise comparisons.

**RESULTS**

**Infusions of E₂ in IL-mPFC Facilitate Extinction of Cocaine Seeking**

Systemic injections of E₂ promote extinction of cocaine seeking in OVX female rats (Twining et al., 2013), but the site of action of E₂ is unknown. Consolidation of extinction of cocaine seeking is dependent on actions within the IL-mPFC (Otis et al., 2014;
Hafenbreidel et al., 2015), therefore, we tested whether localized infusions of E₂ in this region would facilitate extinction in OVX female rats. Following conditioning, rats received IL-mPFC microinfusions of E₂ (n = 21; 5 μg/0.5 μl/side) or HBC vehicle (n = 21) 5 min before extinction (Figure 1). ANOVA revealed no significant trial by group interaction (F(12,480) = 1.004, p > 0.05). However, there was a significant effect of trial by chamber (F(12,480) = 2.554, p < 0.01) and an overall effect of chamber (F(2,80) = 64.152, p < 0.001). Post hoc analysis confirmed that both E₂-treated and HBC vehicle-treated rats spent more time in the previously cocaine-paired chamber than in the saline-paired chamber during the first trial (p < 0.01). Whereas HBC vehicle-treated rats demonstrated a significant preference for the cocaine-paired chamber during trials 1, 2, 3, 4, 6, and 7 (post hoc p < 0.05), E₂-treated rats did not show a significant preference for the cocaine-paired chamber after trial 2 (post hoc p > 0.05). The results suggest that E₂ acts within IL-mPFC to enhance extinction of a cocaine CPP.

E₂ Potentiates IL-mPFC Pyramidal Neuron Excitability

We tested whether bath-application of E₂ alters intrinsic excitability in identified layer 5 IL-mPFC pyramidal neurons (Figure 2A). To control for hormonal manipulations prior to recordings, OVX female rats were systemically injected with E₂ or HBC vehicle for 3 days before they were euthanized for patch-clamp recordings. Slices extracted from OVX female rats that were previously injected with K-252a (25 nM) was bath-applied. The effect of E₂ (25 nM) did not enhance excitability of IL-mPFC neurons from OVX female rats without prior systemic E₂ injections. Slices were first incubated for 20 min in 100 nM K-252a (Montalbano et al., 2013) and then E₂ (25 nM) was bath-applied. The effect of E₂ was blocked by bath-application of K-252a (Figures 3A,B), indicating that Trk receptor blockade prevents E₂-induced potentiation of IL-mPFC neuronal excitability. E₂ reduced fAHP and these changes did not occur when slices are incubated with K-252a (n = 10), E₂ + K-252a (n = 7), and aCSF alone (n = 10), ANOVA revealed an effect of time (F(6,144) = 20.91, p < 0.001), and a treatment by time interaction (F(6,144) = 5.546, p < 0.001). Post hoc tests confirmed that E₂ significantly increased the number of APs compared to controls (p < 0.05). E₂ did not cause membrane depolarization or reduce sAHP (a 1–2 s hyperpolarization that follows a train of APs) but significantly reduced fAHP (a 2–5 ms hyperpolarization that follows a single AP, carried by the calcium- and voltage-dependent BK channel; Storm, 1987) of IL-mPFC neurons (Table 1). Thus, bath-application of E₂ enhances excitability of IL-mPFC pyramidal neurons from OVX female rats previously treated with HBC vehicle.

Slices extracted from OVX female rats that were previously treated with E₂ were incubated in 25 nM E₂ or aCSF and the number of evoked APs were recorded from layer 5 IL-mPFC neurons (Figures 2B,D). The control group (n = 9) received the same number of current injections over time as the E₂ group (n = 9; Figure 2D). Interestingly, bath-application of E₂ (25 nM) did not increase the number of evoked APs in slices extracted from rats that had previously received systemic injections of E₂ (Figure 2D). ANOVA revealed a significant effect of time (F(6,96) = 10.332, p < 0.001), but no significant treatment by time interaction (F(6,96) = 2.933, p > 0.05). In slices from OVX female rats that received systemic injections of E₂, bath-application of E₂ did not enhance excitability of IL-mPFC neurons.

Trk Receptor Blockade Prevents E₂-Induced Potentiation of IL-mPFC Pyramidal Neuron Excitability

We assessed whether Trk receptor blockade prevents E₂-induced enhancement of intrinsic excitability in layer 5 IL-mPFC pyramidal neurons from OVX female rats without prior systemic E₂ injections. Slices were first incubated for 20 min in 100 nM K-252a (Montalbano et al., 2013) and then E₂ (25 nM) was bath-applied. The effect of E₂ was blocked by bath-application of K-252a (Figures 3A,B), indicating that Trk receptor blockade prevents E₂-induced potentiation of IL-mPFC neuronal excitability. E₂ reduced fAHP and these changes did not occur when slices are incubated with K-252a (n = 10), E₂ + K-252a (n = 7), and aCSF alone (n = 10), ANOVA revealed an effect of time (F(6,144) = 20.91, p < 0.001), and a treatment by time interaction (F(6,144) = 5.546, p < 0.001). Post hoc tests confirmed that E₂ significantly increased the number of APs compared to control

![Figure 1](image-url)  
**Figure 1**: Infusions of E₂ into infralimbic-medial prefrontal cortex (IL-mPFC) enhance extinction of a cocaine conditioned place preference (CPP). (A) Coronal drawings showing injector tip placements for IL-mPFC infusions. (B) IL-mPFC infusions (arrows) of E₂ (n = 21) but not vehicle (n = 21) before each CPP trial promoted extinction of a CPP. **p < 0.01, and *p < 0.05. Error bars indicate SEM.
FIGURE 2 | Bath-application of E$_2$ potentiates IL-mPFC pyramidal neuron excitability. (A) Photomicrograph of a biocytin-filled IL-mPFC pyramidal neuron. Scale bar, 50 µm. (B) Individual traces of current-evoked action potentials (APs) from IL-mPFC pyramidal neurons before (top) and after (bottom) bath-application of E$_2$ in slices from ovariectomized (OVX) female rats that were systemically injected with 2-hydroxypropyl-$eta$-cyclodextrin (HBC)-vehicle (left) or with E$_2$ (right). Scale bars, 10 mV (vertical) and 500 ms (horizontal). (C) Compared to artificial cerebral spinal fluid (aCSF) alone ($n = 10$), bath-application of E$_2$ ($n = 10$) enhances intrinsic excitability in IL-mPFC neurons from OVX female rats that were systemically injected with HBC-vehicle prior to recordings. (D) Compared to aCSF alone ($n = 9$), bath-application of E$_2$ ($n = 9$) does not enhance intrinsic excitability in IL-mPFC neurons from OVX female rats that were systemically injected with E$_2$ prior to recordings. *$p < 0.05$. Error bars indicate SEM.

or E$_2$ + K-252a administration ($p < 0.05$). Together, these results show that E$_2$ potentiates excitability in layer 5 IL-mPFC neurons via a TrkB receptor-dependent mechanism.

**E$_2$-Induced Facilitation of Extinction Is disrupted by TrkB Receptor Blockade**

We examined whether TrkB receptor blockade prevented E$_2$-facilitated extinction. Because K-252a does not cross the blood-brain barrier, we used a highly selective TrkB receptor antagonist, ANA-12, that is known to cross the blood-brain barrier effectively (Cazorla et al., 2011; Zhang et al., 2015). All rats received 0.2 mg/kg of E$_2$ (Gresack and Frick, 2006) 1 h prior to each CPP test trial. In addition to E$_2$ injections, rats received either a systemic injection of 0.5 mg/kg of ANA-12 ($n = 9$; Cazorla et al., 2011; Zhang et al., 2015) or vehicle ($n = 10$) 1 h before a CPP trial (Figure 4). ANOVA revealed no significant trial by chamber by group interaction ($F_{(10,170)} = 0.1203$, $p > 0.05$). However, there was a significant effect of trial by chamber ($F_{(10,170)} = 3.926$, $p < 0.001$) and an overall effect of chamber ($F_{(2,34)} = 38.457$, $p < 0.001$). Post hoc analysis confirmed that both E$_2$ + ANA-12-treated and E$_2$ + vehicle-treated rats spent more time in the previously cocaine-paired chamber than in the saline-paired chamber during the first trial ($p < 0.001$). However, E$_2$ + vehicle-treated rats did not show a significant preference for the cocaine-paired chamber during subsequent trials (post hoc $p > 0.05$). In contrast, E$_2$ + ANA-12-treated rats showed a significant preference for the cocaine-paired chamber during trials 2, 3, and 5 (post hoc $p < 0.05$). Therefore, E$_2$-induced facilitation of extinction is impaired by TrkB receptor blockade.

**DISCUSSION**

Systemic E$_2$ administration facilitates extinction of cocaine seeking (Twining et al., 2013), but the locus and mechanism of action have been elusive. Here we show that E$_2$ acts locally within IL-mPFC to facilitate extinction of a cocaine CPP through a BDNF/TrkB-dependent mechanism. First, we found that OVX female rats fail to extinguish in the absence of E$_2$ and that direct bilateral infusions of E$_2$ into IL-mPFC permit extinction
of cocaine seeking. Second, we show that E₂ acts by enhancing intrinsic excitability in layer 5 IL-mPFC pyramidal neurons from OVX female rats, an effect that is blocked in the presence of a Trk inhibitor. Third, we demonstrate that E₂-induced extinction of cocaine seeking is impaired by concurrent blockade of TrkB signaling. Thus, E₂ interacts with BDNF/TrkB signaling in IL-mPFC to enhance neuronal excitability and facilitate extinction of cocaine seeking in female rats.
Our findings are consistent with evidence that E$_2$ is necessary for extinction of both conditioned fear (Milad et al., 2010; Zeidan et al., 2011; Graham and Milad, 2013; Graham and Scott, 2018) and cocaine seeking (Twining et al., 2013). Extinction training results in the formation of a new inhibitory memory that masks the original fear or drug memory. Therefore, E$_2$ could promote extinction of fear or cocaine seeking by enhancing acquisition, retrieval, and/or consolidation of the new extinction memory (Torregrossa and Taylor, 2013), the latter of which is mediated by IL-mPFC (Quirk et al., 2000; Quirk and Mueller, 2008). Previous studies demonstrated that women using hormonal contraceptives, which reduce circulating E$_2$ (Rivera et al., 1999), exhibited poorer extinction recall compared to naturally cycling women (Graham and Milad, 2013). Extinction impairment was also observed in female rats treated with hormonal contraceptives, however, these impairments were restored either by exogenous treatment of E$_2$ or by terminating use of hormonal contraceptive after fear conditioning (Graham and Milad, 2013). Similarly, systemic administration of E$_2$ to OVX female rats promoted extinction of cocaine seeking as compared to vehicle-treated rats (Twining et al., 2013). In that study, E$_2$-treated rats extinguished within a week whereas vehicle-treated rats continued to perseverate for over 6 weeks. Importantly, the extinction impairment observed in vehicle-treated OVX rats was reversed by administration of E$_2$ (Twining et al., 2013). We now show that E$_2$ acts locally within IL-mPFC to facilitate extinction of cocaine seeking in OVX female rats. Whether these findings extend to extinction of drug seeking across drug classes, or to extinction of natural reward seeking, remains to be tested.

In addition to showing that E$_2$ acts within the IL-mPFC to facilitate extinction learning, our results are the first to reveal that E$_2$ enhances intrinsic excitability in IL-mPFC neurons. Greater intrinsic excitability lowers the threshold for synaptic changes and is a neural correlate of extinction learning (Daoudal and Debanne, 2003; Santini et al., 2008; Mozzachiodi and Byrne, 2010; Sehgal et al., 2013). We found that bath-application of E$_2$ increased excitability in IL-mPFC neurons from OVX female rats that did not receive systemic E$_2$ injections prior to recordings. Previously, bath-application of E$_2$ was shown to increase excitability in hippocampal pyramidal neurons (Wong and Moss, 1991; Kumar and Foster, 2002; Carrer et al., 2003; Woolley, 2007; Wu et al., 2011). E$_2$ enhances excitability by regulating the slow Ca$^{2+}$-activated K$^+$ current (sI$_{AHP}$) and suppressing sAHP in hippocampal slices from OVX female rats (Kumar and Foster, 2002; Carrer et al., 2003; Wu et al., 2011). In IL-mPFC neurons, however, E$_2$ did not alter sAH but reduced fAHP. One reason for this may be that sAH and fAH are differentially modulated depending on the type of learning. For example, changes in sAH occur following fear conditioning (Santini et al., 2008), eye-blink conditioning (Moyer et al., 1996; Thompson et al., 1996), and Morris water maze learning (Oh et al., 2003), whereas fAHP (but not sAHP) is reduced after extinction learning (Santini et al., 2008). Thus, both extinction and E$_2$ may enhance excitability of IL-mPFC neurons through suppression of fAHP.

Bath-application of E$_2$ did not induce excitability or reduce fAHP in IL-mPFC neurons from OVX female rats that received systemic injections of E$_2$ prior to recordings. These results have also been observed in hippocampal neurons where pretreatment of E$_2$ prevented the effects of bath-applied E$_2$ on excitability (Carrer et al., 2003). The lack of excitability changes may be due to a negative feedback mechanism as E$_2$ has been shown to facilitate seizures (Newmark and Penny, 1980; Woolley, 2000). Systemic injections of E$_2$ could have downregulated ERs in IL-mPFC and reduced the effects of E$_2$ bath-application to prevent the induction of seizures. Future work is needed to elucidate exactly how pretreatment with E$_2$ influences the extinction circuitry.

Our findings show that E$_2$ potentiates IL-mPFC neuronal excitability via Trk receptor activation. Behaviorally, E$_2$ may aid extinction of cocaine seeking by regulating BDNF/Trk signaling. BDNF is a likely target as it has been shown to promote extinction of cocaine seeking and fear learning (Peters et al., 2010; Otis et al., 2014), whereas the TrkB receptor antagonist, ANA-12, impaired extinction of cocaine seeking in male rats (Otis et al., 2014). Similarly, we demonstrate that ANA-12 prevents the facilitating effects of E$_2$ on extinction of a cocaine CPP in OVX female rats. Our data support previous work that E$_2$-BDNF interactions may be necessary for learning-related plasticity. For example, E$_2$ replacement in young adult OVX female rats enhances BDNF protein levels in the olfactory bulbs (Jezierski and Sohrabji, 2000, 2001), hippocampus (Gibbs, 1998; Allen and McCarson, 2005; Fortress et al., 2014), cortex (Sohrabji et al., 1995; Allen and McCarson, 2005) amygdala (Liu et al., 2001; Zhou et al., 2005), septum (Gibbs, 1999; Liu et al., 2001), dorsolateral area of the bed nucleus terminalis, and the lateral habenular nucleus (Gibbs, 1999). E$_2$ has also shown to increase BDNF expression in the entorhinal cortex of aged OVX female rats (Bimonte-Nelson et al., 2004) as well as in the hippocampus of gonadectomized male mice (Solum and Handa, 2002). Moreover, BDNF is necessary for E$_2$ regulation of dendritic spines and ultimately synaptic transmission. E$_2$-mediated increases in dendritic spine density are attenuated by inhibiting TrkB receptors with K-252a in hippocampal slice cultures (Sato et al., 2007). Furthermore, aromatase knockout mice, which have depleted neuron-derived E$_2$, had a large decrease in both BDNF protein as well as dendritic spine density and these deficits were rescued by treatment with estradiol benzoate (Sasahara et al., 2007; Lu et al., 2019). Although E$_2$ influences multiple brain structures to enhance cognitive processes, evidence to date indicates that E$_2$ primarily targets IL-mPFC to promote extinction of fear- and drug-associated memories. For example, intrahippocampal infusions of E$_2$ did not facilitate extinction of a cocaine CPP in OVX female rats (preliminary data, not shown). Moreover, systemic administration of E$_2$ to naturally cycling rats enhanced c-fos activity in IL-mPFC relative to prelimbic mPFC and central amygdala during fear extinction recall (Maeng et al., 2017). Thus, E$_2$ and BDNF may act synergistically to potentiate plasticity within the IL-mPFC and strengthen extinction learning.

E$_2$ is known to modulate BDNF through regulation of the gene encoding BDNF as this gene contains a sequence similar to the estrogen response element (ERE; Sohrabji et al., 1995). Through the classical genomic mechanism,
estrogens bind to intracellular ERs to form complexes, which bind to ERE in the DNA to influence gene transcription. ER-ligand complexes bind to the ERE-like motif on the BDNF gene and may regulate BDNF expression (Sohrabji et al., 1995). Moreover, both E2 and BDNF share common signal transduction pathways and transcription factors. These include signaling through the extracellular regulated protein kinase (ERK; Toran-Allerand et al., 1999; Yamada and Nabeshima, 2003; Boulware et al., 2013; Lu et al., 2019) the phosphatidylinositol 3-kinase (PI3-K; Mizuno et al., 2003; Znamensky et al., 2003; Fortress et al., 2013), Ca\(^{2+}\)/calmodulin-dependent protein kinase II (CaMKII; Sawai et al., 2002; Blanquet et al., 2003) and cAMP response element-binding protein (CREB; Ernfors and Bramham, 2003; McEwen et al., 2001; Boulware et al., 2005; Lu et al., 2019). Although there are indirect findings that E2 and BDNF interact to enhance memory, much more work is required to understand how E2 activates specific signaling pathways to regulate BDNF/Trk expression.

In conclusion, our data provide the first evidence that E2 localized within II-mPFC facilitates extinction in female rats through a BDNF/TrkB-dependent mechanism. These findings have implications for the treatment of cocaine abuse in women. Cocaine dependence has increased among adolescent women between the ages of 12–17, and more women are admitted for cocaine abuse treatment compared to their male counterparts (Lejuez et al., 2007). So far, little progress has been made towards sex-specific therapeutic approaches for cocaine addiction. Treatment options, such as extinction-based exposure therapy, have had limited success without any pharmacological adjuncts (Conklin and Tiffany, 2002). Thus, pharmacological enhancement of E2 or BDNF/TrkB signaling may prove to be clinically relevant for the treatment of disorders in women involving maladaptive memories and behavioral inflexibility such as addiction or posttraumatic stress disorder.

**DATA AVAILABILITY**

The datasets generated for this study are available on request to the corresponding author.

**ETHICS STATEMENT**

All experimental protocols were approved by the Institutional Animal Care and Use Committee at the University of Wisconsin-Milwaukee in accordance with National Institute of Health guidelines.

**AUTHOR CONTRIBUTIONS**

HY, KF and DM designed experiments. HY and DM analyzed the data and wrote the manuscript. HY, CS, MH, JT, AF and DM carried out the experiments.

**FUNDING**

This study was supported by National Institute on Drug Abuse, National Institutes of Health (NIH) R01 DA038042 to DM, and a grant (00044) from the Puerto Rico Science, Technology and Research Trust to DM.

**ACKNOWLEDGMENTS**

We are grateful to James M. Otis, PhD, Carolyyn Rafa Todd and Megha Sehgal, PhD for technical assistance.

**REFERENCES**

Aguirre, C. C., and Baudry, M. (2009). Progesterone reverses 17β-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. *Eur. J. Neurosci.* 29, 447–454. doi: 10.1111/j.1460-9568.2008.06591.x

Allen, A. L., and McCarson, K. E. (2005). Estrogen increases nociception-evoked brain-derived neurotrophic factor gene expression in the female rat. *Neuroendocrinology* 81, 193–199. doi: 10.1159/000087002

Becker, J. B., and Hu, M. (2008). Sex differences in drug abuse. *Front. Neuroendocrinol.* 29, 36–47. doi: 10.1016/j.yfrne.2007.07.003

Bimonte-Nelson, H. A., Nelson, M. E., and Granholm, A. C. E. (2004). Progesterone counteracts estrogen-induced increases in neurotophins in the aged female rat brain. *Neuroreport* 15, 2659–2663. doi: 10.1097/00001756-200412300-00021

Blanquet, P. R., Mariani, J., and Derer, P. (2003). A calcium/calmodulin kinase pathway connects brain-derived neurotrophic factor to the cyclic AMP-responsive transcription factor in the rat hippocampus. *Neuroscience* 118, 477–490. doi: 10.1016/s0306-4522(02)00963-6

Bobzean, S. A., Dennis, T. S., and Perrotti, L. I. (2014). Acute estradiol treatment affects the expression of cocaine-induced conditioned place preference in ovarietoimized female rats. *Brain Res. Bull.* 103, 49–53. doi: 10.1016/j.brainresbull.2014.02.002

Boulware, M. I., Heisler, J. D., and Frick, K. M. (2013). The memory-enhancing effects of hippocampal estrogen receptor activation involve metabotropic glutamate receptor signaling. *J. Neurosci.* 33, 15184–15194. doi: 10.1523/jneurosci.1716-13.2013

Boulware, M. I., Weick, J. P., Becklund, B. R., Kuo, S. P., Groth, R. D., and Mermelstein, P. G. (2005). Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. *J. Neurosci.* 25, 5066–5078. doi: 10.1523/JNEUROSCI.1427-05.2005

Carrer, H. F., Araque, A., and Buño, W. (2003). Estradiol regulates the slow Ca\(^{2+}\)-activated K\(^{+}\) current in hippocampal pyramidal neurons. *J. Neurosci.* 23, 6338–6344. doi: 10.1523/jneurosci.23-15-06338.2003

Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., and Rognan, D. (2011). Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. *J. Clin. Invest.* 121, 1846–1857. doi: 10.1172/jci43992

Conklin, C. A., and Tiffany, S. T. (2002). Applying extinction research and theory to cue-exposure addiction treatments. *Addiction* 97, 155–167. doi: 10.1046/j.1360-0443.2002.00014.x

Daniel, J. M. (2006). Effects of oestrogen on cognition: what have we learned from basic research? *J. Neuroendocrinol.* 18, 787–795. doi: 10.1111/j.1365-2826.2006.01471.x

Daoudal, G., and Debanne, D. (2003). Long-term plasticity of intrinsic excitability: learning rules and mechanisms. *Learn. Mem.* 10, 456–465. doi: 10.1101/lm.64103

Doncheck, E. M., Urbanik, L. A., DeBaker, M. C., Barron, L. M., Liddiard, G. T., Doncheck, E. M., Urbanik, L. A., DeBaker, M. C., Barron, L. M., Liddiard, G. T., Tuscher, J. J., et al. (2018). 17β-estradiol potentiates the reinstatement of cocaine seeking in female rats: role of the prelimbic prefrontal cortex and cannabinoid type-1 receptors. *Neuropsychopharmacology* 43, 781–790. doi: 10.1038/npp.2017.170
Elman, I., Karlsgodt, K. H., and Gastfriend, D. R. (2001). Gender differences in cocaine craving among non-treatment-seeking individuals with cocaine dependence. Am. J. Drug Alcohol Abuse 27, 193–202. doi: 10.1081/ada-100103705

Erfors, P., and Brainham, C. R. (2003). The coupling of a trkβ tyrosine residue to LTP. Trends Neurosci. 26, 171–173. doi: 10.1016/S0166-2236(03)00064-x

Evans, S. M., and Foltin, R. W. (2010). Does the response to cocaine differ as a function of sex or hormonal status in human and non-human primates? Horm. Behav. 58, 13–21. doi: 10.1016/j.yhbeh.2009.08.010

Fernandez, S. M., Lewis, M. C., Pechenino, A. S., Harbarger, L. L., Orr, P. T., Gresack, J. E., et al. (2008). Estradiol-induced enhancement of object memory consolidation involves hippocampal extracellular signal-regulated kinase activation and membrane-bound estrogen receptors. J. Neurosci. 28, 8660–8667. doi: 10.1523/jneurosci.1968.2008.08.028

Fortress, A. M., Fan, L., Orr, P. T., Zhao, Z., and Frick, K. M. (2013). Estradiol-induced object recognition memory consolidation is dependent on activation of mTOR signaling in the dorsal hippocampus. Learn. Mem. 20, 147–155. doi: 10.1101/lm.027372.112

Frick, K. M. (2012). Building a better hormone therapy? How understanding of age-related memory decline. Behav. Neurosci. 126, 29–53.

Frick, K. M. (2015). Molecular mechanisms underlying the memory-enhancing effects of estradiol. Horm. Behav. 74, 4–18. doi: 10.1016/j.yhbeh.2015.05.001

Frick, K. M., Fernandez, S. M., Bennett, J. C., Prange-Kiel, J., Maclusky, N. J., and Leranth, C. (2004). Behavioral training interferes with the ability of gonadal hormones to increase CA1 spine synapse density in ovariectomized female rats. Endocrinology 145, 5906–5915. doi: 10.1210/jc.2004-0150

Gibbs, R. B. (1999). Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain. Brain Res. 844, 20–27. doi: 10.1016/S0006-8993(99)01880-6

Graham, B. M., and Milad, M. R. (2013). Blockade of estrogen by hormonal replacement and increases Bdnf promoter acetylation in middle-aged female mice. Learn. Mem. 21, 457–467. doi: 10.1101/lm.034033.113

Hafenbreidel, M., Twining, R. C., Todd, C. R., and Mueller, D. (2015). Blocking estrogen decreases the AHP amplitude in CA1 pyramidal neurons. J. Neurophysiol. 88, 621–626. doi: 10.1152/jn.00266.2014

Larson, E. B., Anker, J. J., Gildon, L. A., Fons, K. S., and Carroll, M. E. (2007). Effects of estrogen and progesterone on the escalation of cocaine self-administration in female rats during extended access. Exp. Clin. Psychopharmacol. 15, 461–471. doi: 10.1016/j.eclp.2007.15.5.461

Lejuez, C. W., Bornovolova, M. A., Reynolds, E. K., Daughters, S. B., and Curtin, J. J. (2007). Risk factors in the relationship between gender and crack/cocaine. Exp. Clin. Psychopharmacol. 15, 165–175. doi: 10.1016/j.eclp.2007.15.2.165

Liu, Y., Fowler, C. D., Young, L. J., Yan, Q., Insel, T. R., and Wang, Z. (2001). Expression and estrogen regulation of brain-derived neurotrophic factor gene and protein in the forebrain of female prairie voles. J. Comp. Neurol. 453, 499–514. doi: 10.1002/cne.1156

Lu, Y., Sareddy, G. R., Wang, J., Wang, R., Li, Y., Dong, Y., et al. (2019). Neuron-derived estrogen regulates synaptic plasticity and memory. J. Neurosci. 39, 2792–2809. doi: 10.1523/JNEUROSCI.1970-18.2019

Lynch, W. J., Roth, M. E., and Carroll, M. E. (2002). Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology 164, 121–137. doi: 10.1007/s00213-002-1183-2

Lynch, W. J., Roth, M. E., Mickelberg, J. L., and Carroll, M. E. (2001). Role of estrogen in the acquisition of intravenously self-administered cocaine in female rats. Pharmacol. Biochem. Behav. 68, 641–646. doi: 10.1016/s0091-3057(00)00455-5

Maeng, L. Y., Cover, K. K., Taha, M. B., Landau, A. J., Milad, M. R., and Lebrón-Milad, K. (2017). Estradiol shifts interactions between the infralimbic cortex and central amygdala to enhance fear extinction memory in female rats. J. Neurosci. Res. 95, 163–175. doi: 10.1002/jnr.23826

McCance-Katz, E. F., Carroll, K. M., and Rounsaville, B. J. (1999). Gender differences in treatment-seeking cocaine abusers—implications for treatment and prognosis. Am. J. Addict. 8, 300–311. doi: 10.1177/105504999305703

McCarty, C. R., Du, X., Wu, Y. C., and Hill, R. A. (2018). Investigating the interactive effects of sex steroid hormones and brain-derived neurotrophic factor deficiency during adolescence on hippocampal NMDA receptor expression. Int. J. Endocrinol. 2018:7231915. doi: 10.1155/2018/7231915

McEwen, B., Akama, K., Alves, S., Brake, W. G., Bulloch, K., Lee, S., et al. (2001). Tracking the estrogen receptor in neurons: implications for estrogen-induced synapse formation. Proc. Natl. Acad. Sci. Ú S A 98, 7093–7100. doi: 10.1073/pnas.12114698

Milad, M. R., Zeidan, M. A., Contero, A., Pittman, R. K., Klibanski, A., Rauch, S. L., et al. (2010). The influence of gonadal hormones on conditioned fear extinction in healthy humans. Neuroscience 168, 652–658. doi: 10.1016/j.neuroscience.2010.04.030

Mizuno, M., Yamada, K., He, J., Nakajima, A., and Nabeshima, T. (2003). Improvement of BDNF receptor TrkB in spatial memory formation. Learn. Mem. 10, 108–115. doi: 10.1101/lm.56003

Montalbano, A., Bai, G., Papadia, D., Tongiorgi, E., and Sciancalepore, M. (2013). Blockade of BDNF signaling turns chemically-induced long-term potentiation into long-term depression. Hippocampus 23, 879–889. doi: 10.1002/hipo.22144

Moyer, J. R. Jr., Thompson, L. T., and Disterhoft, J. F. (1996). Trace eyelid conditioning increases CA1 excitability in a transient and learning-specific manner. J. Neurosci. 16, 5536–5546. doi: 10.1523/jneurosci.16-17.0536.1996

Mozzachiodi, R., and Byrne, J. H. (2010). More than synaptic plasticity: role of non-associative plasticity in learning and memory. Trends Neurosci. 33, 17–26. doi: 10.1016/j.tins.2009.10.001

Newmark, M. E., and Perry, J. K. (1980). Catamenial epilepsy: a review. Epilepsia 21, 281–300. doi: 10.1111/1528-1157.1980.tb00474.x

O’Brien, M. S., and Anthony, J. C. (2005). Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000–2001. Neuropsychopharmacology 30, 1006–1018. doi: 10.1038/sj.npp.1300763

Oh, M. M., Kuo, A. G., Wu, W. W., Sametsky, E. A., and Disterhoft, J. F. (2003). Watermaze learning enhances excitability of CA1 pyramidal neurons. J. Neurophysiol. 90, 2171–2179. doi: 10.1152/jn.00177.2002

Otis, J. M., Dashew, K. B., and Mueller, D. (2013). Neurobiological dissociation of retrieval and reconsolidation of cocaine-associated memory. J. Neurosci. 33, 1271a–1281a. doi: 10.1523/JNEUROSCI.3463-12.2013
Yousuf et al.

Frontiers in Behavioral Neuroscience | www.frontiersin.org

Conflict of Interest Statement: The authors declare that the conducted research in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Yousuf, Smits, Hafnerbreidt, Tuscher, Fortress, Frick and Mueller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.